# RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

> **NCT02128113** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 307 (actual)

## Conditions studied

- Corneal Endothelial Cell Loss
- Ocular Pain
- Ocular Inflammation
- Cataract Surgery

## Interventions

- **DRUG:** Vehicle Ophthalmic Solution
- **DRUG:** Omaveloxolone Ophthalmic Suspension 0.5%
- **DRUG:** Omaveloxolone Ophthalmic Suspension 1%

## Key facts

- **NCT ID:** NCT02128113
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-31
- **Primary completion:** 2015-02-28
- **Final completion:** 2015-04-30
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128113, "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02128113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*